Browse by Medical Category
Wednesday, December 11, 2013
Trial will provide guidance on cost-effective ways to treat this severe form of peripheral artery disease
Boston, MA – A team of researchers from Brigham and Women's Hospital (BWH), Boston Medical Center (BMC) and Massachusetts General Hospital (MGH) has been awarded $25 million by the National Institutes of Health (NIH) to conduct a four-year, randomized clinical trial—the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia (CLI).
The principal investigators of the BEST-CLI trial are Alik Farber, MD, division chief of Vascular and Endovascular Surgery at BMC; Matthew Menard, MD, co-director of Endovascular Surgery at BWH; and Kenneth Rosenfield, MD, section head of Vascular Medicine and Intervention at MGH.
CLI is the most severe form of peripheral arterial disease, which is caused by chronic inflammation and atherosclerotic plaque build-up in the arteries of the legs. Symptoms caused by reduced blood flow to the legs and feet include ischemic leg pain, non-healing wounds and gangrene. If untreated, CLI can often lead to leg amputation. The aging of the national population and the rising rate of diabetes have led to an increase in both peripheral arterial disease and CLI.
According to the study investigators, while both open surgery and endovascular interventions are used to treat CLI, it is not clear which approach works best in patients who are candidates for both treatment options.
"Currently, there is a lack of consistency and clarity as to what approach—minimally invasive endovascular or open surgery—is best for our patients," said Farber. "The BEST-CLI Trial will provide answers to many unanswered questions, most importantly what treatment works best for whom."
"The CLI population is an exceptionally complex and challenging group of patients to treat," added Menard. "In addition to providing much needed information on the functional outcomes and cost-effectiveness of the two treatment strategies being tested, the BEST-CLI Trial will provide a unique opportunity for interdisciplinary collaboration between all of the subspecialties currently providing care to CLI patients.
Added Rosenfield: "The BEST-CLI Trial will be a robust and rigorously conducted clinical trial which promises to greatly enhance our understanding of CLI—a devastating disorder that affects millions of Americans. We are grateful to the National Institutes of Health for recognizing the enormous impact of this scourge and look forward to expanding the evidence base to optimize care and outcomes for these patients with advanced cardiovascular disease."
The BEST-CLI trial will be highly innovative in both its design and its collaborative nature. It will provide, for the first time, urgently needed clinical guidance for CLI management by using:
The trial will enroll 2,100 participants and be conducted at 120 clinical centers in the United States and Canada. The New England Research Institutes (Watertown, MA) will be serving as the data coordinating center.
Massachusetts General Hospital founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham’s medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, and has more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation’s first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information and resources, please visit BWH’s online newsroom.
Boston Medical Center is a private, not-for-profit, 496-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. Committed to providing high-quality health care to all, the hospital offers a full spectrum of pediatric and adult care services including primary and family medicine and advanced specialty care with an emphasis on community-based care. Boston Medical Center offers specialized care for complex health problems and is a leading research institution. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet—15 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit www.bmc.org.
Back to Top